Suchen
Fibrobiologics Inc
FBLGZur Watchlist hinzufügen
1.050USD
-0.030-2.78%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
5.47MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Fibrobiologics Inc Unternehmen
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Fibrobiologics Inc Informationen
BörsenkürzelFBLG
Name des UnternehmensFibrobiologics Inc
IPO-datumJan 31, 2024
CEOO'Heeron (Pete)
Anzahl der mitarbeiter13
WertpapierartOrdinary Share
GeschäftsjahresendeJan 31
Addresse455 E. Medical Center Blvd
StadtHOUSTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl77598
Telefon12816715150
Websitehttps://fibrobiologics.com/
BörsenkürzelFBLG
IPO-datumJan 31, 2024
CEOO'Heeron (Pete)
Führungskräfte von Fibrobiologics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
9.00K
--
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
3.06K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
375.00
--
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
--
--
Mr. Richard Cilento, Jr.
Mr. Richard Cilento, Jr.
Independent Director
Independent Director
--
--
Ms. Stacy Coen
Ms. Stacy Coen
Independent Director
Independent Director
--
--
Mr. Matthew Link
Mr. Matthew Link
Independent Director
Independent Director
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
9.00K
--
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
3.06K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
375.00
--
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
--
--
Mr. Richard Cilento, Jr.
Mr. Richard Cilento, Jr.
Independent Director
Independent Director
--
--
Ms. Stacy Coen
Ms. Stacy Coen
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Thu, May 14
Aktualisiert: Thu, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Golden Knight Inc LP
6.48%
O'Heeron (Peter)
5.72%
Armistice Capital LLC
4.98%
The Lind Partners, LLC
3.03%
Vanguard Capital Management, LLC
1.30%
Andere
78.49%
Aktionäre
Aktionäre
Anteil
Golden Knight Inc LP
6.48%
O'Heeron (Peter)
5.72%
Armistice Capital LLC
4.98%
The Lind Partners, LLC
3.03%
Vanguard Capital Management, LLC
1.30%
Andere
78.49%
Aktionärstypen
Aktionäre
Anteil
Corporation
6.48%
Individual Investor
6.14%
Investment Advisor
5.99%
Hedge Fund
5.53%
Investment Advisor/Hedge Fund
1.49%
Research Firm
0.21%
Venture Capital
0.04%
Andere
74.14%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
139
258.88K
4.97%
-83.81K
2025Q4
125
5.16M
16.27%
--
2025Q3
125
5.16M
16.27%
+26.14K
2025Q2
124
5.13M
16.68%
-1.32M
2025Q1
115
6.45M
16.82%
+104.96K
2024Q4
107
5.96M
16.68%
+467.89K
2024Q3
99
5.49M
10.74%
+2.00M
2024Q2
74
3.47M
1.58%
+2.95M
2024Q1
20
483.30K
0.00%
+483.30K
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Golden Knight Inc LP
337.49K
9.61%
+53.75K
+18.94%
Mar 13, 2026
O'Heeron (Peter)
297.91K
8.48%
+2.58K
+0.87%
Mar 13, 2026
BlackRock Institutional Trust Company, N.A.
23.87K
0.68%
+2.13K
+9.81%
Dec 31, 2025
Geode Capital Management, L.L.C.
17.44K
0.5%
+2.99K
+20.70%
Dec 31, 2025
Cascade Financial Partners, LLC
15.73K
0.45%
+825.00
+5.54%
Dec 31, 2025
Millennium Management LLC
14.43K
0.41%
-7.88K
-35.34%
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
Texas Capital Texas Small Cap Equity Index ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Mar 25, 2026
Merger
20→1
Datum
Ex-Dividendentag
Art
Verhältnis
Mar 25, 2026
Merger
20→1
